Hrtwr Intrntl Inc (HTWR) 58.20 $HTWR 76.9% Retu
Post# of 273319
Posted On: 09/02/2016 3:20:47 PM
Hrtwr Intrntl Inc (HTWR) 58.20 $HTWR
76.9% Return Seen to Date on SmarTrend HeartWare International Call (HTWR)
Comtex SmarTrend(R) - Tue Aug 30, 12:13AM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 3 months, HeartWare International has returned 76.93% as of today's recent price of $57.98.
HTWR: 58.20 (+0.22)
Medtronic, on Behalf of Its Subsidiary Heartware International, Inc., Announces Offer to Repurchase HeartWare's 3.50% Convertible Senior Notes Due 2017 and 1.75% Convertible Senior Notes Due 2021
Globe Newswire - Fri Aug 26, 7:30AM CDT
DUBLIN - Aug. 26, 2016 - Medtronic plc (NYSE: MDT), on behalf of its indirect, wholly-owned subsidiary HeartWare International, Inc., today announced that, in connection with the completion of the acquisition of HeartWare by Medtronic, HeartWare has commenced an offer to repurchase (the "Convertible Notes Repurchase Offer"
, at the option of each holder, any and all of its outstanding 3.50% Convertible Senior Notes due 2017 (the "2017 Notes" and 1.75% Convertible Senior Notes due 2021 (the "2021 Notes," and together with the 2017 Notes, the "Notes". On August 23, 2016, pursuant to the terms and conditions of a definitive merger agreement between the companies, Medtronic completed the tender offer for all of the outstanding shares of common stock of HeartWare, consummated the merger of HeartWare with a wholly-owned subsidiary of Medtronic and terminated trading of HeartWare's common stock on The Nasdaq Stock Market LLC, each of which constituted a Fundamental Change (as defined in each of the indentures governing the Notes (the "Indentures" ) and a Make-Whole Fundamental Change (as defined in each of the Indentures), triggering HeartWare's obligation to commence the Convertible Notes Repurchase Offer and the conversion rights described below.
MDT: 87.36 (+0.38), HTWR: 58.20 (+0.22)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.36 (+0.38), GWPH: 82.33 (+0.05), QDEL: 21.58 (-0.16), HTWR: 58.20 (+0.22), NUVA: 66.48 (+0.42)
Medtronic Completes Acquisition of HeartWare International
Globe Newswire - Tue Aug 23, 7:54AM CDT
Broadens Heart Failure Leadership Into Growing Circulatory Support Sector
MDT: 87.36 (+0.38), HTWR: 58.20 (+0.22)
Uptrend Call Working As HeartWare International Stock Rises 76.9% (HTWR)
Comtex SmarTrend(R) - Mon Aug 22, 12:39PM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 months, HeartWare International has returned 76.93% as of today's recent price of $57.98.
HTWR: 58.20 (+0.22)
HeartWare International Up 76.7% Since SmarTrend Uptrend Call (HTWR)
Comtex SmarTrend(R) - Fri Aug 05, 12:12AM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 months, HeartWare International has returned 76.75% as of today's recent price of $57.92.
HTWR: 58.20 (+0.22)
Shares of HTWR Up 76.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 28, 12:41PM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 month, HeartWare International has returned 76.56% as of today's recent price of $57.86.
HTWR: 58.20 (+0.22)
HeartWare International Reports $68.7 Million In Second Quarter 2016 Revenue
PR Newswire - Thu Jul 28, 7:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced total revenue of $68.7 million for the quarter ended June 30, 2016, compared to $73.6 million for the same period in 2015 and $55.1 million for the first quarter of 2016. Total revenue decreased approximately 7% year-over-year, which is primarily attributable to the third quarter 2015 completion of enrollment of the company's ENDURANCE2 Destination Therapy (DT) clinical trial, which contributed approximately $5 million to revenue in the second quarter of 2015.
MDT: 87.36 (+0.38), HTWR: 58.20 (+0.22)
HeartWare Presentation At The Goldman Sachs 37th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Wed Jun 01, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that members of HeartWare's executive management are scheduled to participate in a webcast session at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016 at 10:40 a.m. PT (1:40 p.m. ET). The conference is being held June 7-9 in Rancho Palos Verdes, California.
HTWR: 58.20 (+0.22)
HeartWare International Shares Down 16.8% Since SmarTrend's Sell Call (HTWR)
Comtex SmarTrend(R) - Fri May 20, 1:51PM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 16.84% as of today's recent price of $28.01.
HTWR: 58.20 (+0.22)
HeartWare International Has Returned 19.9% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri May 13, 1:03AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 19.86% as of today's recent price of $27.00.
HTWR: 58.20 (+0.22)
HeartWare Presentation At The Bank Of America Merrill Lynch 2016 Health Care Conference To Be Webcast
PR Newswire - Thu May 05, 3:15PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 4:20 p.m. PT (7:20 p.m. ET). The conference is being held May 10-12 in Las Vegas.
HTWR: 58.20 (+0.22)
Why Heartware International's Shares Are Sinking 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:17AM CDT
SOURCE: HEARTWARE INTERNATIONAL, INC. What: After reporting first-quarter financial results that fell shy of industry watchers' forecasts, shares of Heartware International were tumbling by 12.4% at 11:30 a.m. EST. So what: The maker of...
HTWR: 58.20 (+0.22)
HeartWare International Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue derived from HeartWare® Ventricular Assist System (HVAD® System) sales of $55.1 million for the first quarter ended March 31, 2016, compared to $70.0 million in revenue for the same period in 2015.
HTWR: 58.20 (+0.22)
HeartWare Completes Enrollment In HVAD® System LATERAL Study(TM)
PR Newswire - Wed Apr 27, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare® Ventricular Assist System (HVAD® System) LATERAL Study(TM).
HTWR: 58.20 (+0.22)
HeartWare Announces HVAD® System Scientific Presentations At The International Society For Heart And Lung Transplantation 36th Annual Meeting
PR Newswire - Wed Apr 20, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced a series of scientific presentations, highlighting the clinical and commercial use of the HVAD® System, at the International Society for Heart and Lung Transplantation (ISHLT) 36th Annual Meeting and Scientific Sessions to be held at the Marriott Wardman Park Hotel in Washington, D.C. on April 27-30, 2016.
HTWR: 58.20 (+0.22)
HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast
PR Newswire - Tue Apr 19, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call and webcast to discuss its financial results for the three months ended March 31, 2016, on Wednesday, May 4, 2016 at 8:00 a.m. ET. The company plans to release the financial results prior to the conference call and webcast, during which management will discuss the company's financial results, highlights from the first quarter and business outlook.
HTWR: 58.20 (+0.22)
Ventricular Assist Device Market Analysis - Key Players are Abiomed, HeartWare International & Berlin Heart - Research and Markets
BusinessWire - Wed Mar 30, 7:37AM CDT
Research and Markets has announced the addition of the "Ventricular Assist Device Market Analysis by Product (Left, Right, Bi- Ventricular Assist Devices), and Segment Forecasts To 2022" report to their offering.
HTWR: 58.20 (+0.22)
STOCK ALERT: Rosen Law Firm Reminds HeartWare International Inc. Investors of Important Deadline in Class Action- HTWR
BusinessWire - Wed Feb 10, 2:47PM CST
Rosen Law Firm, a global investor rights law firm, reminds purchasers of HeartWare International Inc. securities (NASDAQ:HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the "Class Period" of the important March 22, 2016 lead plaintiff deadline. The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws.
HTWR: 58.20 (+0.22)
HEARTWARE INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against HeartWare International, Inc.
BusinessWire - Tue Feb 09, 4:08PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased or otherwise acquired the common stock of HeartWare International, Inc. ("HeartWare" or the "Company" (Nasdaq:HTWR) between June 10, 2014 and January 11, 2016, inclusive (the "Class Period".
HTWR: 58.20 (+0.22)
76.9% Return Seen to Date on SmarTrend HeartWare International Call (HTWR)
Comtex SmarTrend(R) - Tue Aug 30, 12:13AM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 3 months, HeartWare International has returned 76.93% as of today's recent price of $57.98.
HTWR: 58.20 (+0.22)
Medtronic, on Behalf of Its Subsidiary Heartware International, Inc., Announces Offer to Repurchase HeartWare's 3.50% Convertible Senior Notes Due 2017 and 1.75% Convertible Senior Notes Due 2021
Globe Newswire - Fri Aug 26, 7:30AM CDT
DUBLIN - Aug. 26, 2016 - Medtronic plc (NYSE: MDT), on behalf of its indirect, wholly-owned subsidiary HeartWare International, Inc., today announced that, in connection with the completion of the acquisition of HeartWare by Medtronic, HeartWare has commenced an offer to repurchase (the "Convertible Notes Repurchase Offer"
, at the option of each holder, any and all of its outstanding 3.50% Convertible Senior Notes due 2017 (the "2017 Notes" and 1.75% Convertible Senior Notes due 2021 (the "2021 Notes," and together with the 2017 Notes, the "Notes". On August 23, 2016, pursuant to the terms and conditions of a definitive merger agreement between the companies, Medtronic completed the tender offer for all of the outstanding shares of common stock of HeartWare, consummated the merger of HeartWare with a wholly-owned subsidiary of Medtronic and terminated trading of HeartWare's common stock on The Nasdaq Stock Market LLC, each of which constituted a Fundamental Change (as defined in each of the indentures governing the Notes (the "Indentures" ) and a Make-Whole Fundamental Change (as defined in each of the Indentures), triggering HeartWare's obligation to commence the Convertible Notes Repurchase Offer and the conversion rights described below. MDT: 87.36 (+0.38), HTWR: 58.20 (+0.22)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.36 (+0.38), GWPH: 82.33 (+0.05), QDEL: 21.58 (-0.16), HTWR: 58.20 (+0.22), NUVA: 66.48 (+0.42)
Medtronic Completes Acquisition of HeartWare International
Globe Newswire - Tue Aug 23, 7:54AM CDT
Broadens Heart Failure Leadership Into Growing Circulatory Support Sector
MDT: 87.36 (+0.38), HTWR: 58.20 (+0.22)
Uptrend Call Working As HeartWare International Stock Rises 76.9% (HTWR)
Comtex SmarTrend(R) - Mon Aug 22, 12:39PM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 months, HeartWare International has returned 76.93% as of today's recent price of $57.98.
HTWR: 58.20 (+0.22)
HeartWare International Up 76.7% Since SmarTrend Uptrend Call (HTWR)
Comtex SmarTrend(R) - Fri Aug 05, 12:12AM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 months, HeartWare International has returned 76.75% as of today's recent price of $57.92.
HTWR: 58.20 (+0.22)
Shares of HTWR Up 76.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 28, 12:41PM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 month, HeartWare International has returned 76.56% as of today's recent price of $57.86.
HTWR: 58.20 (+0.22)
HeartWare International Reports $68.7 Million In Second Quarter 2016 Revenue
PR Newswire - Thu Jul 28, 7:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced total revenue of $68.7 million for the quarter ended June 30, 2016, compared to $73.6 million for the same period in 2015 and $55.1 million for the first quarter of 2016. Total revenue decreased approximately 7% year-over-year, which is primarily attributable to the third quarter 2015 completion of enrollment of the company's ENDURANCE2 Destination Therapy (DT) clinical trial, which contributed approximately $5 million to revenue in the second quarter of 2015.
MDT: 87.36 (+0.38), HTWR: 58.20 (+0.22)
HeartWare Presentation At The Goldman Sachs 37th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Wed Jun 01, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that members of HeartWare's executive management are scheduled to participate in a webcast session at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016 at 10:40 a.m. PT (1:40 p.m. ET). The conference is being held June 7-9 in Rancho Palos Verdes, California.
HTWR: 58.20 (+0.22)
HeartWare International Shares Down 16.8% Since SmarTrend's Sell Call (HTWR)
Comtex SmarTrend(R) - Fri May 20, 1:51PM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 16.84% as of today's recent price of $28.01.
HTWR: 58.20 (+0.22)
HeartWare International Has Returned 19.9% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri May 13, 1:03AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 19.86% as of today's recent price of $27.00.
HTWR: 58.20 (+0.22)
HeartWare Presentation At The Bank Of America Merrill Lynch 2016 Health Care Conference To Be Webcast
PR Newswire - Thu May 05, 3:15PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 4:20 p.m. PT (7:20 p.m. ET). The conference is being held May 10-12 in Las Vegas.
HTWR: 58.20 (+0.22)
Why Heartware International's Shares Are Sinking 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:17AM CDT
SOURCE: HEARTWARE INTERNATIONAL, INC. What: After reporting first-quarter financial results that fell shy of industry watchers' forecasts, shares of Heartware International were tumbling by 12.4% at 11:30 a.m. EST. So what: The maker of...
HTWR: 58.20 (+0.22)
HeartWare International Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue derived from HeartWare® Ventricular Assist System (HVAD® System) sales of $55.1 million for the first quarter ended March 31, 2016, compared to $70.0 million in revenue for the same period in 2015.
HTWR: 58.20 (+0.22)
HeartWare Completes Enrollment In HVAD® System LATERAL Study(TM)
PR Newswire - Wed Apr 27, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare® Ventricular Assist System (HVAD® System) LATERAL Study(TM).
HTWR: 58.20 (+0.22)
HeartWare Announces HVAD® System Scientific Presentations At The International Society For Heart And Lung Transplantation 36th Annual Meeting
PR Newswire - Wed Apr 20, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced a series of scientific presentations, highlighting the clinical and commercial use of the HVAD® System, at the International Society for Heart and Lung Transplantation (ISHLT) 36th Annual Meeting and Scientific Sessions to be held at the Marriott Wardman Park Hotel in Washington, D.C. on April 27-30, 2016.
HTWR: 58.20 (+0.22)
HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast
PR Newswire - Tue Apr 19, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call and webcast to discuss its financial results for the three months ended March 31, 2016, on Wednesday, May 4, 2016 at 8:00 a.m. ET. The company plans to release the financial results prior to the conference call and webcast, during which management will discuss the company's financial results, highlights from the first quarter and business outlook.
HTWR: 58.20 (+0.22)
Ventricular Assist Device Market Analysis - Key Players are Abiomed, HeartWare International & Berlin Heart - Research and Markets
BusinessWire - Wed Mar 30, 7:37AM CDT
Research and Markets has announced the addition of the "Ventricular Assist Device Market Analysis by Product (Left, Right, Bi- Ventricular Assist Devices), and Segment Forecasts To 2022" report to their offering.
HTWR: 58.20 (+0.22)
STOCK ALERT: Rosen Law Firm Reminds HeartWare International Inc. Investors of Important Deadline in Class Action- HTWR
BusinessWire - Wed Feb 10, 2:47PM CST
Rosen Law Firm, a global investor rights law firm, reminds purchasers of HeartWare International Inc. securities (NASDAQ:HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the "Class Period"
of the important March 22, 2016 lead plaintiff deadline. The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws. HTWR: 58.20 (+0.22)
HEARTWARE INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against HeartWare International, Inc.
BusinessWire - Tue Feb 09, 4:08PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased or otherwise acquired the common stock of HeartWare International, Inc. ("HeartWare" or the "Company"
(Nasdaq:HTWR) between June 10, 2014 and January 11, 2016, inclusive (the "Class Period". HTWR: 58.20 (+0.22)
(0)
(0)